Sudden cardiac death (SCD) is one of the most significant and challenging problems facing modern medicine today given its unpredictable nature. The evaluation of the patient at risk for sudden cardiac death still remains a complex task. The use of ICDs (implantable cardioverter defibrillators) remains the mainstay of primary prevention of sudden cardiac death. However, much remains to be determined on how best to identify patients at high risk of sudden cardiac death who would most benefit from ICD implantations. This paper will review the current issues in the risk assessment of sudden cardiac death and non-invasive markers of sudden death.
INtRODUCtION
Sudden cardiac death (SCD) is "death due to cardiac causes, preceded by abrupt loss of consciousness within 1 hour of the onset of acute symptoms." Annual incidence is 0.36 to 1.28 per 1000 inhabitants. 1 Coronary artery disease (CAD) is the most common cause in the developed world, while in younger patients, the major causes are inherited arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), anomalous coronary arteries, and hereditary channelopathies, for example, long QT syndrome (LQTS). The prevalence of SCD is three to four fold higher in men.
Approximately 80% of victims of SCD do not survive to hospital discharge. This high mortality underscores the importance of prevention of SCD. Although the use of ICDs (implantable cardioverter defibrillators) remains the mainstay of prevention of sudden cardiac death, there remain challenges especially in the identification of patients who are at high risk of sudden cardiac death who will benefit most from ICD implantation. This issue is of particular clinical importance in view of the fact that prophylactic ICD implantation is expensive in terms of device cost with an estimated cost-effectiveness ranging from USD $25 300 to USD $50 700 per lifeyear. 2 In principle, ICD implantation will be more cost-effective when used for patients at high risk of arrhythmic death. Additional risk stratification of patients may improve patient selection for the ICD and thereby enhance its cost-effectiveness. Therefore, accurate risk stratification is a vital step towards reducing SCD. Although many tests of SCD vulnerability have been examined, there is little consensus on which test, in addition to the left ventricular ejection fraction (LVEF), should be used to determine whether or not to implant an ICD in a given patient. Over the past few years, more efforts have been concentrated on examining existing and novel markers in patients to identify those who will benefit from an ICD. This paper will review the current literature on the risk assessment of sudden cardiac death and non-invasive markers of sudden cardiac death.
Primary prevention refers to the prevention of SCD in individuals without a history of cardiac arrest or sustained VT. Secondary prevention refers to the prevention of SCD in those patients who have survived a prior cardiac arrest or sustained VT. Primary prevention of SCD consists of three main strategies: 1. Identifying individuals at risk for SCD; 2. Pharmacologic agents and surgical/percutaneous techniques for control of arrthymias; 3. Implantable devices. Multiple clinical trials have established that ICD use results in improved survival compared with antiarrhythmic agents for primary 6, 7 and secondary prevention of SCD. 8 However, recommendations for consideration of ICD therapy, particularly those for primary prevention, apply only to patients who are receiving optimal medical therapy and have a reasonable expectation of survival with good functional status for more than one year. The device-based guidelines were last been updated in 2008 and are shown in Table 1 (See overleaf ). 3. ICD therapy is not indicated in patients with significant psychiatric illnesses that may be aggravated by device implantation or that may preclude systematic follow-up. 4. ICD therapy is not indicated for NYHA Class IV patients with drug refractory congestive heart failure who are not candidates for cardiac transplantation or implantation of a CRT device that incorporates both pacing and defibrillation capabilities. 5. ICD therapy is not indicated for syncope of undetermined cause in a patient without inducible ventricular tachyarrhythmias and without structural heart disease. 6. ICD therapy is not indicated when ventricular fibrillation or VT is amenable to surgical or catheter ablation (e.g. atrial arrhythmias associated with Wolff-Parkinson-White syndrome, right ventricular or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence of structural heart disease). 7. ICD therapy is not indicated for patients with ventricular tachyarrhythmias due to a completely reversible disorder in the absence of structural heart disease (e.g., electrolyte imbalance, drugs, or trauma).
# Risk factors in HCOM :
The major risk factors include prior cardiac arrest, spontaneous sustained VT, spontaneous nonsustained VT, family history of SCD, syncope, LV thickness greater than or equal to 30 mm, and an abnormal blood pressure response to exercise * Risk factors in ARVD: Significant risk factors include induction of VT during electrophysiological testing, detection of nonsustained VT on noninvasive monitoring, male gender, severe RV dilation, and extensive RV involvement
Markers Of Abnormal Myocardial Substrate imaging Modalities for Assessment of ischaemia and Scarring
The majority of episodes of SCD occurred in individuals with coronary artery disease, the primary disease process resulting in both myocardial ischaemia and scarring. However, the extent to which acute ischaemia plays a role in initiating a trigger for SCD remains unclear. Other than the traditional tools of 2-dimensional echocardiograms, radionuclide imaging in assessing ejection fraction, Cardiac Magnetic Resonance Imaging (CMR) has emerged as a potentially powerful tool in the assessment of ejection fraction and evaluation of ischaemia or scarring in ischaemic and nonischaemic patients. 
Assessment of Ejection Fraction
One of the most powerful predictors of sudden cardiac death is impaired left ventricular ejection fraction, and this should be assessed in all SCD survivors. LVEF is one of the oldest and most widely used tests for risk stratification. The Multicenter Post Infarction Program (MPIP) described the inverse relationship between LVEF, measured by radionuclide ventriculography, and cardiac mortality in patients with recent acute myocardial infarct. The mortality rate rises steeply with a hazard ratio of 3.5 in patients with reduced LVEF less than 30% compared with patients with ejection fraction greater than 30%. 9, 10 Table 2 (See overleaf ) lists several clinical trials done in patients that incorporated ICD therapy which used EF as a primary risk assessment tool. A reduced LVEF of 35% or below was a major eligibility criterion for enrolling patients in the six randomised trials shown which enrolled patients along with one or more additional risk-stratifying characteristics; one trial, Multicenter Automatic Defibrillator Implantation Trial (MADIT) II used LVEF <0.31 alone to select patients with coronary heart disease for ICD prophylaxis. 11 
Cardiac MRi
With the use of different imaging techniques within a single scan, cardiac MRI has emerged to be a promising tool in the cardiac risk assessment arena. These techniques include spin echo sequences (which are high resolution still images that identify abnormal myocardium through differences in intrinsic contrast) and the use of ECG gating to acquire images at each stage of the cardiac cycle. In ECG gating, blood typically appears bright due to the contrast properties of blood and its rapid flow. Cardiac MRI also has the ability to determine heart chamber volumes accurately without geometric assumptions, provide accurate measurements of stroke volume, ejection fraction, and assess the severity of perfusion abnormalities and ischaemia.
Infarct imaging is best seen after giving a contrast agent, typically one containing gadolinium chelated to diethylenetriamine penta-acetic acid (DTPA). With a special sequence, Inversion Recovery (IR), a bolus of gadolinium can be washed in and out of normal myocardium quickly. In the presence of myocyte necrosis, expanded extracellular space can cause retention of gadolinium molecules, and delayed (15-20 minutes after gadolinium administration) gadolinium enhancement (DGE) signifies myocardial damage. The contrast agent also has slower uptake and efflux kinetics in areas of fibrosis versus normal muscle. DGE as the result of myocardial infarction typically occurs in coronary perfusion territories and involves at least the subendocardium. The volume of DGE correlates well with myocyte necrosis on triphenyltetrazolium chloride staining and can therefore be used to quantify infarct size. 12 The transmural extent of DGE is also a measure of myocardial viability and predicts the likelihood of functional recovery after revascularisation of hypokinetic or akinetic myocardial segments. 13 These parameters may be of use in the assessment of sudden death risk. In a study by Bello et al 14 infarct mass and surface area predicted the inducibility of VT better than LVEF. The presence of midwall fibrosis in subjects with non-ischaemic cardiomyopathy conferred a five-fold risk for sudden death or VT. 15 In a more recent study by Iles et al, 16 the authors looked at the potential of CMR as a non-invasive tool in assessing sudden cardiac death. One hundred and three patients meeting criteria for ICD implantation for primary Proceedings of Singapore Healthcare  Volume 20  Number 4  2011 prevention were followed-up. Regional fibrosis was identified with delayed gadolinium enhancement (DGE) on CMR before device implantation. After a median follow-up of 573 days, DGE identified regional fibrosis in 31 of 61 (51%) patients with non-ischaemic cardiomyopathy (NICM) and in all 42 patients with ischaemic cardiomyopathy (ICM). Left ventricular ejection fraction was similar in patients with and without device therapy and those with or without LGE. There were no ICD discharges in the NICM group without LGE, which was significantly lower than the rate observed in both the ICM patients (P=0.04) and the NICM patients with LGE (P <0.01). The authors concluded that patients with advanced cardiomyopathy and myocardial fibrosis demonstrated by DGE on CMR have a high likelihood of appropriate ICD therapy. Correspondingly, absence of LGE may indicate a lower risk for malignant ventricular arrhythmias.
ECG Markers intraventricular Conduction Delay
Intraventricular conduction defects with QRS duration ≥120 milliseconds have been found to be associated with increased mortality in post-MI patients and in patients with congestive heart failure. 17 Patients with LBBB have been shown to have an increased sudden death rate at one year with a hazard ratio of 1.348 (95% Confidence Interval [CI] 1.051-1.729, P=0.188). 18 Wide QRS complexes could signify a more LV dysfunction with an increased risk for adverse events or may directly contribute to LV dysfunction by causing mechanical dyssynchrony. In cardiomyopathy, especially if non-ischaemic, a wide QRS predisposes to bundle-branch reentrant VT. 19 
Left ventricular Hypertrophy
Left ventricular hypertrophy is commonly used as a marker for disease involving the heart such as hypertensive heart disease. The electrocardiogram often shows signs of increased voltage from the heart in individuals with LVH, so this is often used as a screening test to determine who should undergo further testing (see Fig. 2A ). LVH increased the risk of arrhythmic death by 35% irrespective of electrophysiological findings and was the sole predictor of arrhythmic events independent of total mortality in MUSTT. 21 23 This technique is limited in the presence of bundle branch block or significant intraventricular conduction delay.
A positive SAECG in a post-MI population has a positive predictive accuracy of 14% to 29% when used to predict major arrhythmic events (sustained VT or sudden death), and a normal SAECG has a negative predictive accuracy of 95% to 99%. 24, 25 In MUSTT, unsustained VT patients with an LVEF <0.30 and a unfiltered QRS >114 milliseconds had a 36% five-year incidence of arrhythmic death or nonfatal cardiac arrest, while those with an EF 0.30-0.40 and a normal SAECG had a 13% five-year incidence of arrhythmic death or cardiac arrest. 21 
Fragmented QRS Complexes (fQRS)
Fragmented QRS complexes on ECGs (Fig. 2C ) (see overleaf ) are described as an extra spike (notching of the R or S wave) in the absence of any bundle branch block and are easily identified on a routine ECG. In the presence of a bundle branch block, two notches or more are required for identification.
They are a sign of depolarisation abnormality and their presence appears to be a significant marker for future cardiac events in patients with coronary heart disease. In a study of almost 1000 patients, There are still limitations in the use of fQRS as an assessment tool. fQRS on a 12-lead ECG requires an optimal low pass filter setting (100 or 150 Hz). Fragmentation may be missed with a filter setting of 40 or 60 Hz. It is to be emphasised that fQRS is a non-specific finding and should only be interpreted in the presence of pertinent clinical evidence of myocardial scar such as the presence of ischaemic heart disease.
Autonomic Nervous System (ANS)
ANS abnormalities influence the risk of malignant ventricular arrhythmias or sudden death in a profound way. [27] [28] [29] [30] Neural modulation of RR intervals 
ECG Markers Heart Rate variability
Heart rate variability analysis is the evaluation of beat to beat variability of the R-R interval and is thought to be a reflection of autonomic tone. Data is obtained from digitised 24-hour ambulatory ECG recordings. The most commonly used measures are SDNN, the standard deviation of all normalto-normal RR intervals; SDANN, the standard deviation of all five-minute average RR intervals; pNN50, the proportion of beats varying by more than 50 milliseconds from the preceding QRS; and rMSSD, the square root of the squares of successive differences between the RR intervals. 31, 32 The first large clinical study demonstrating the predictive value of heart rate variability (HRV) measurements after myocardial infarction was the MPIP study. In this study, SDNN was a strong ECG predictor of outcome with a relative risk of 3.4 of three-year allcause mortality in patients with SDNN <50ms. The sensitivity and positive predictive accuracy from the study was 33%. 33 
Abnormalities in Resting Heart Rate
Tachycardia irrespective of heart disease has been shown to be an independent risk factor for SCD. Allcause mortality and SCD increased with increasing resting heart rate over 23 years follow-up in 5,713 men aged 42 to 53 without cardiovascular disease. 36 European Systematic Coronary Risk Evaluation (SCORE) investigators found heart rate an independent predictor of death in 21,766 men after adjustment for cardiorespiratory fitness. 37 Heart Rate Turbulence (HRT) The concept of heart rate turbulence was introduced by Schidmt in 1999. 38 HRT refers to the physiological biphasic response of the sinus node to a premature ventricular beat and is an indicator of short-term flunctuation in sinus cycle length. In healthy subjects and low-risk patients, ventricular ectopics are followed by brief heart rate acceleration then deceleration over a 10-15 beat period. Response in high risk patients is blunted.
The practical drawback is that the method depends on ventricular or atrial ectopics (typically 200) occurring during Holter monitoring. The absence of heart rate turbulence predicts SCD risk and total mortality after MI. In the Innovative Stratification of Arrhythmic Risk (ISAR) study in 2,611 post-MI patients, heart rate turbulence and EF were the only independent predictors of all-cause mortality and appropriate ICD shock. 39 In another multivariate analysis, absence of HRT was the strongest predictor of mortality in a group of survivors post-myocardial infarct with a hazard ratio of 2.8. 40 Baroreflex Sensitivity (BRS) Baroreflex sensitivity (BRS) has been used to stratify risk after MI. BRS is measured by determining the response of RR intervals to alterations in blood pressure with the use of α-adrenergic agonists such as phenylephrine. Patients with depressed BRS (<3 ms/mm Hg) and depressed HRV (SDNN <70 ms) had a 17% versus 2% mortality risk in the subgroup compared with the group with normal values for both tests. 41 More studies are needed to assess if BRS can be developed into a clinically useful tool for selecting patients for ICD prophylaxis.
Role of Cardiac Sympathetic innervation imaging
Advances in the imaging of the sympathetic system of the heart may provide diagnostic and prognostic markers for the identification of highrisk patients and predict response to therapies and interventions as well. This can be assessed by using I-MIBG (Metaiodobenzylguanidine), an analogue of norepinephrine to look at heart to mediastinum ratio uptake and myocardial washout. Decreased uptake and increased washout are associated with worse prognosis. A meta-analysis of 18 studies with a total of 1,755 patients showed that heart failure patients with decreased heart to mediastinum uptake or increased myocardial MIBG washout have a worse prognosis compared with those with normal myocardial MIBG parameters. 42 
Repolarisation Abnormalities
Observations in the CCU prompted the concept of "warning arrhythmias," that is, premature ventricular contractions (PVCs) that are a prelude to sustained, potentially lethal, ventricular arrhythmias. Hazard ratios derived from the analysis of MPIP suggest that the probability of dying in patients with LVEF below 0.30, more than three VPCs per hour, and unsustained VT was 13 times that in patients with none of these predictors of high risk. The evidence from MPIP also found an independent association between ventricular arrhythmias and death in the early years after myocardial infarction. 43 While ventricular arrhythmias after myocardial infarction continue to be an important risk predictor, it is not a proven therapeutic target for anti-arrthymics. Suppression of the PVCs with anti-arrhythmic drugs had been associated with increased mortality. The Cardiac Arrhythmia Suppression Trial (CAST) was a definitive NHLBI-sponsored study carried out in patients with previous myocardial infarction with reduced LVEF and unsustained ventricular arrhythmias to test the suppression hypothesis, that is, suppressing ventricular arrhythmias will improve survival. Anti-arrthymics studied included encainide and fleicanide. However in April 1989, NHLBI stopped CAST recruitment because of increased mortality on encainide and flecainide. 44
ECG Markers QT interval
The QT interval reflects the duration of ventricular depolarisation and repolarisation and is quantified by measuring the QT interval on the 12-lead ECG and correcting for heart rate using the Bazett or Fridericia formulas. 45 Abnormal QT prolongation has been identified as a marker of increased risk for sudden death with a hazard ratio 2.17 (95% CI: 0.67-7.45, P <0.05). 46 Other variables of the QT interval that may be suitable markers of sudden death include increased beat-to-beat variability in the QT duration and QT dispersion. The electrophysiologic mechanism is complex and is likely to involve disturbances in repolarising and depolarising currents, with a resultant propensity to tachyarrthymias. 47, 48 QT variability QT variability can be derived from a sequence of RR intervals using short-term, high frequency ECG recordings. The heart rate mean (HRm) and variance (HRv) and QT interval mean (QTm) and variance (QTv) are electronically computed from the ECGs. A normalised QT variability index (QTVI) is then computed as a log ratio between the QT interval and heart rate variability. In the MADIT II study, QT variability was measured in Holter recordings in 476 patients who also received an ICD. In a Cox regression model that included race, time after myocardial infarction, NYHA class and LVEF, QTVI was an independent predictor of VT/VF with a hazard ratio of 1.80, (95% CI: 1.09-2.60, P=0.018). 49 
QT Dispersion
QT dispersion (QTD) is measured by taking the difference between the longest and shortest QT interval measured on a 12-lead ECG, 50 and is a measure of variability of the QT interval. There is evidence that QTD is useful in risk stratification of patients with LQTS. 51 QTD has been found to be an independent predictor of cardiovascular mortality in two large studies which looked at populations in which the majority of patients had no known heart disease, one looking at an elderly population in Rotterdam, 52 and the other looking at middle-aged and elderly native Americans (the Strong Heart study). 53 In each study, abnormal QT dispersion was associated with an approximately two-fold increase in risk of cardiovascular mortality. The duration of repolarisation is proportional to the previous diastolic interval, so that action potential and QT duration shorten as heart rate increases. Action potential restitution as measured by QT/RR slope is the relationship between action potential duration and the preceding diastolic interval, and the steeper the slope of restitution, the greater the change in action potential. In a model that contained age, LVEF,SDNN and creatinine, Pathak et al 54 studied 175 heart failure patients and found that a QT/RR slope >0.28 over 24-hours was associated with a multivariate hazard ratio of 3.4 (95% CI: 1.43-8.4, P=0.0058) for sudden death.
Repolarisation abnormalities in patients after myocardial infarct (MI) have recently been hypothesised to result in mechanical dispersion of the left ventricle, which can be measured as regional heterogeneity of contraction by myocardial strain.
In a prospective study including 85 post-MI patients who met primary and secondary ICD prevention criteria, longitudinal strain was measured by speckle tracking echocardiography. 55 The standard deviation of time to maximum myocardial shortening in a 16segment LV model was calculated as a parameter of mechanical dispersion. Mechanical dispersion was found to be more pronounced in post-MI patients with recurrent arrhythmias. Mechanical dispersion was greater in ICD patients with recorded ventricular arrhythmias compared with those without (85±29 ms vs. 56±13 ms, P <0.001). By Cox regression, mechanical dispersion was a strong and independent predictor of arrhythmias requiring ICD therapy (hazard ratio: 1.25 per 10 ms increase, 95% CI: 1.1-1.4, P <0.001). The use of myocardial strain imaging may provide useful information about susceptibility for ventricular arrhythmias after MI in the future.
Microvolt electrical Alternans
Microvolt electrical alternans is variability of the ECG waveform on alternate beats. Sir Thomas Lewis 56 first recognised electrical alternans in electrocardiograms as a pathophysiological manifestation that occurred in serious heart disease or, in normal persons, when the heart rate was very rapid. The T wave is measured at an identical time relative to the QRS in multiple consecutive complexes. Spectral analysis is used to differentiate minor alterations in T wave morphology occurring at the alternans frequency (every second beat) from alterations caused by respiration or other background noise. 57 Indeed, a combination of MTWA with reduced LVEF via a two-tiered screening approach has shown promise to risk stratify patients and identify patients who may theoretically derive most benefit from ICD implantation. [59] [60] [61] early Repolarisation Syndrome Early repolarisation is a slurring or notching producing a hump-like feature called a J wave, typically found at the junction at the end of the QRS complex and the beginning of the ST segment. In a normal ECG, the transition of ventricular depolarisation into ventricular repolarisation corresponds on the surface ECG to this J-point. Deviation of the J-point from the isoelectric line leads to a J-deflection, producing a concave upward curve towards the T wave. This phenomenon of early repolarisation typically involves the anterior precordial leads (V1-V3) and is seen in approximately two to five per cent of the population. 62 Early repolarisation previously was felt to be a rather benign feature; however, isolated case reports and independent case studies have shown its potential arrhythmogenic effects.
Recently, data has looked into early repolarisation localised to the inferolateral leads. Haïssaguerre et al 63 evaluated the clinical association between early repolarisation in the inferolateral leads and syncope/SCD related ventricular arrhythmias in 206 case subjects with a prior history of idiopathic ventricular fibrillation (IVF). Early repolarisation prevalence was compared between case subjects who had previously experienced an episode of IVF prior to the study and control subjects with no known heart disease. Early repolarisation occurred more frequently in the case subjects with IVF than the control subjects (31% vs. 5%, P <0.001). In the study, electrocardiography was performed during an arrhythmic period of PVCs or IVF in 18 case subjects, and a consistent increase in the amplitude of early depolarisation so that the J-point amplitude increased from 2.6±1 mm to 4.1±2 mm (P <0.001).
The study by Tikkanen et al 64 was a prevalence study to assess early depolarisation pattern and its long-term prognosis in a large, middle-aged Finnish community (mean age, 44 ± 8 years) with a mean follow-up of 30 years. Findings showed that the J-point elevation of at least 0.1 mV in the inferior leads was associated with an increased risk of cardiovascular mortality (adjusted relative risk, 1.28; 95% CI, 1.04-1.59; P=0.03) when compared to these elevations in the lateral leads (adjusted relative risk of 1.34; 95% CI, 1.04-1.74; P=0.03). Based on the findings above, early repolarisation in the inferior leads appeared to be a strong predictor of death from cardiac causes or from arrhythmia than J-point elevation in the lateral leads. In addition to the location of the earlyrepolarisation pattern, the amplitude of the J-point elevation also had great prognostic value. There was a significantly higher risk of death from cardiac causes among subjects with a markedly elevated J point (>0.2 mV) than among those with a more moderate elevation (≥0.1 mV).
Current Guidelines in Management and Prevention of Sudden Cardiac Death
Evaluation of SCD survivors should always begin with a complete history and physical examination covering patient medications, family history, drug use and risk factors. Table 3 (see overleaf ) .
Challenges Facing Current Risk Stratification Strategies
Despite the extensive research done in evaluating the contributory factors of sudden cardiac death, there remain multiple challenges in risk stratification of sudden cardiac death. These include the limited ability to identify the timing and sequence of sudden death and the fact that the etiology of sudden cardiac death is multi-factorial. The lack of a "gold standard" of a test further confounds and adds to the complexity of the situation. Thus far, patients with depressed ejection fraction represent a high risk group who may present with adverse clinical events resulting in increased morbidity and mortality and a cut-off value of LVEF 35% or below has traditionally been used in several large, multicentre studies to select those patients considered at highest risk of cardiovascular events and sudden death. However, there are still limitations to the current guidelines in place using LVEF as the main basis for risk stratification. In the MUSTT study, patients whose only risk factor is EF ≤30% have a predicted two-year arrhythmic death risk <5%. 65 The criteria used to select patients for ICD prophylaxis for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), that is, reduced left ventricular ejection fraction (LVEF) less than 36% and New York Heart Association Class II or III heart failure symptoms, are commonly used to select patients in clinical practice. Unfortunately, fewer than 80% of patients selected using these criteria have an appropriate ICD shock and the absolute reduction in deaths is 7.2% during five years of follow-up. 66 This may be due to considerable risk heterogeneity among patients with low LVEF and multiple factors may interact with LVEF to influence overall cardiovascular risk. Furthermore, conventional methods of measuring LVEF using 2D-echo are limited by factors such as the subjective nature of the test, variations in LV structure and shape and potential changes in LVEF with remodelling over time. This may result in a proportion of patients not receiving optimal care to both identify and treat this condition. As most patients bear the inconvenience of ICD therapy as well as risk of physical and psychological complications without deriving benefit from their implanted device, the low ICD usage in patients reinforces the motivation towards a continuing effort to improve risk stratification.
One of the other challenges facing risk stratification today is while it is common for a marker to have strong independent association with outcome; it does not contribute meaningfully to improved risk discrimination. Many risk factors are continuous variables that display significant overlap in distribution between those who will and those who will not experience sudden cardiac death. Because of the substantial overlap, these tests applied singly cannot provide good discrimination. Another important question that remains unresolved is when and how often monitoring should be undertaken.
The goals of risk stratification strategies include:
(1) better identification of patients who are at risk for sudden cardiac death but are yet to be identified, and (2) identification of patients with low ejection fraction who are currently classified as high risk, but with appropriate evaluation may be reclassified as having low risk for sudden cardiac death and therefore may not need an ICD. If this is achievable, ICD therapy can be deployed to those who need it and not to those who do not need it. Improved objective ways to help identify which patients are at greatest risk will allow for more intensive and frequent monitoring of high risk patients in order to prevent clinical deterioration and lower re-hospitalisation rates. Furthermore, the healthcare system bears substantial expenses for prophylactic ICDs that never give therapy for ventricular arrhythmias. From the health economics point of view, an improved system to risk stratify potential candidates who will benefit from ICD insertion will help to channel limited resources to patients who are most likely to benefit.
Risk Stratification techniques and ICD therapy
The most widely used risk stratification strategy employs a low ejection fraction as a main criterion. While such a strategy has been shown to be effective, most patients who experience sudden cardiac death do not fall within the low ejection fraction criteria used in such a strategy. Furthermore, it has also been demonstrated that there are further sub-categories of risk even within this low ejection fraction group, such that those with a high risk for sudden cardiac death can be In 2001, Bailey et al 67 performed an analysis of existing techniques to identify a strategy for identifying patients at risk for sudden cardiac death via a multi-stage approach via non-invasive means. The techniques employed included SAECG and LVEF (stage 1); the use of Holter monitoring (Stage 2) and electrophysiology studies (Stage 3). They calculated the number of patients that would be classified into a low risk group, high risk group, and an unstratified group. In this analysis, 80% of the population can be classified as low risk with a 2.9% probability of a major arrhythmic event, while 11.8% would be classified as high risk with a 41.4% risk of a major arrhythmic event. Finally, 8.2% of the population would be unstratified with an 8.9% probability of a major arrhythmic event over two years. The limitation of this analysis is that this was a statistical analysis based on numerous studies reporting sensitivities and specificities and not an actual tested strategy; as yet there is no major clinical trial.
Data that suggest that non-invasive tests in combination with clinical variables are important in risk stratification is still emergent. While the combination of low ejection fraction with either abnormal signal-averaged electrocardiogram (tested in the CABG-Patch Trial 68 ) or abnormal heart variability immediately following myocardial infarction (as tested in the DINAMIT Trial 69 ) revealed no survival advantage to those treated with an ICD, the combination of low ejection fraction and inducible ventricular tachycardia tested in the MADIT6 and MUSTT7 studies, did demonstrate an improved survival with the ICD. Finally, the combination of low ejection fraction (≤35%) and New York Heart Association class (SCD-HeFT) 70 or ejection fraction <30% (MADIT-II) 11 has been shown to identify patients who have improved survival with an ICD. differentiated from those with a very low risk for sudden cardiac death. While ejection fraction is useful for identifying high risk patients, it does not discriminate well between those at risk and those at low risk for sudden death. The non-invasive determination of a patient's risk for developing life-threatening ventricular arrhythmias and evaluation of non-invasive markers of sudden cardiac death could be enhanced with the use of ambulatory ECG monitoring based techniques such as the use of Holter or implantable loop recorders.
